Kisha Patel

Kisha Patel

Auto-generated profile, based on publicly available information

Kisha Patel

Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
KSKirit Singh
Kirit Singh
KHKelly M. Hotchkiss
Kelly M. Hotchkiss
KPKisha K. Patel
Kisha K. Patel
DWDaniel S. Wilkinson
Daniel S. Wilkinson
AMAditya Mohan
Aditya Mohan
JSJohn H. Sampson
John H. Sampson
Glioblastoma is an immunologically ‘cold’ tumor, which are characterized by absent or minimal numbers of tumor-infiltrating lymphocytes (TILs). For those tumors that have been invaded by lymphocytes, they are profoundly exhausted and ineffective. While many immunotherapy approaches seek to reinvigorate immune cells at the tumor, this requires TILs to be present. Therefore, to unleash the full potential of immunotherapy in glioblastoma, the trafficking of lymphocytes to the tumor is highly desirable. However, the process of T cell recruitment into the central nervous system (CNS) is tightly regulated. Naïve T cells may undergo an initial licensing process to enter the migratory phenotype necessary to enter the CNS. T cells then must express appropriate integrins and selectin ligands to interact with transmembrane proteins at the blood–brain barrier (BBB). Finally, they must interact with antigen-presenting cells and undergo further licensing to enter the parenchyma. These T cells must then navigate the tumor microenvironment, which is rich in immunosuppressive factors. Altered tumoral metabolism also interferes with T cell motility. In this review, we will describe these processes and their mediators, along with potential therapeutic approaches to enhance trafficking. We also discuss safety considerations for such approaches as well as potential counteragents.

1 June 2018 in Acta Biomaterialia
Verified
Journal Article
Closed access
MMMaziar Mohammadi
Maziar Mohammadi
KPKisha Patel
Kisha Patel
SASeyedeh P. Alaie
Seyedeh P. Alaie
RSRon B. Shmueli
Ron B. Shmueli
CBCagri G Besirli
Cagri G Besirli
JGJordan J. Green
Jordan J. Green

30 September 2024 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
APAyush Pant
Ayush Pant
AJAanchal Jain
Aanchal Jain
YCYiyun Chen
Yiyun Chen
KPKisha Patel
Kisha Patel
LSLaura Saleh
Laura Saleh
CJChristopher M. Jackson
Christopher M. Jackson
Regulatory T cells (Treg) are important players in the tumor microenvironment. However, the mechanisms behind their immunosuppressive effects are poorly understood. We found that CCR6–CCL20 activity in tumor-infiltrating Tregs is associated with greater glycolytic activity and ablation of Ccr6 reduced glycolysis and lactic acid production while increasing compensatory glutamine metabolism. Immunosuppressive activity toward CD8+ T cells was abrogated in Ccr6−/− Tregs due to reduction in activation-induced glycolysis. Furthermore, Ccr6−/− mice exhibited improved survival across multiple tumor models compared to wild-type mice and Treg and CD8+ T-cell depletion abrogated the improvement. In addition, Ccr6 ablation further promoted the efficacy of anti-PD-1 therapy in a preclinical glioma model. Follow-up knockdown of Ccl20 with siRNA also demonstrated improvement in antitumor efficacy. Our results unveil CCR6 as a marker and regulator of Treg-induced immunosuppression and identify approaches to target the metabolic determinants of Treg immunosuppressive activity.

19 June 2019 in Operative Neurosurgery
Verified
Journal Article
Closed access
PDF file
YXYuanxuan Xia
Yuanxuan Xia
TKTimothy Y Kim
Timothy Y Kim
LMLeila A Mashouf
Leila A Mashouf
KPKisha K Patel
Kisha K Patel
RXRisheng Xu
Risheng Xu
MLMichael Lim
Michael Lim
BACKGROUND: Sacrificing the superior petrosal vein (SPV) is controversial during a microvascular decompression (MVD). There have been multiple reports of complications including life-threatening brainstem infarction and cerebellar edema. OBJECTIVE: To analyze the potential for vascular complications when the SPV is sacrificed during an MVD. METHODS: Retrospective chart review was performed to identify all MVDs for trigeminal neuralgia and hemifacial spasm from 2007 to 2018 at 1 institution. Cases with ≥1 mo of follow-up were included and SPV sacrifice was noted. The primary outcome was complications related to SPV sacrifice including sinus thrombosis, cerebellar edema, and midbrain or pontine infarction. Imaging was used to confirm all potential vascular complications noted in medical records. Fisher's exact test and unpaired t-tests were used to compare between groups. RESULTS: A total of 732 MVD cases were identified and 592 met inclusion criteria with an average follow-up of 11.8 ± 16.4 mo and a male-to-female ratio of 1:2.2. The SPV was sacrificed in 217 cases and retained in 375 cases. No SPV-related vascular complications were found in this study. Two unrelated cases of vascular complications were identified and both were in the nonsacrificed group. One case involved cerebellar bleeding while the other was an ipsilateral transverse sinus thrombosis that was present preoperatively. CONCLUSION: In MVDs, there is no difference in the rate of vascular complications when the SPV is sacrificed compared to preserved. To best visualize a cranial nerve and optimize safe decompression, surgeons should feel free to sacrifice the SPV.

1 April 2020 in Journal of Neurosurgery
Verified
Journal Article
Closed access
PDF file
TKTimothy Y. Kim
Timothy Y. Kim
CJChristopher M. Jackson
Christopher M. Jackson
YXYuanxuan Xia
Yuanxuan Xia
LMLeila A. Mashouf
Leila A. Mashouf
KPKisha K. Patel
Kisha K. Patel
MLMichael Lim
Michael Lim
OBJECTIVE: Trigeminal neuralgia (TN) is a neuropathic pain disorder characterized by severe, lancinating facial pain that is commonly treated with neuropathic medication, percutaneous rhizotomy, and/or microvascular decompression (MVD). Patients who are not found to have distinct arterial compression during MVD present a management challenge. In 2013, the authors reported on a small case series of such patients in whom glycerin was injected intraoperatively into the cisternal segment of the trigeminal nerve. The objective of the authors’ present study was to report their updated experience with this technique to further validate this novel approach.METHODS: The authors performed a retrospective analysis of data obtained in patients in whom glycerin was directly injected into the inferior third of the cisternal portion of the trigeminal nerve. Seventy-four patients, including 14 patients from the authors’ prior study, were identified, and demographic information, intraoperative findings, postoperative course, and complications were recorded. Fisher’s exact test, unpaired t-tests, and Kaplan-Meier survival curves using Mantel log-rank test were used to compare the 74 patients with a cohort of 476 patients who received standard MVD by the same surgeon.RESULTS: The 74 patients who underwent MVD and glycerin injection had an average follow-up of 19.1 ± 18.0 months, and the male/female ratio was 1:2.9. In 33 patients (44.6%), a previous intervention for TN had failed. On average, patients had an improvement in the Barrow Neurological Institute Pain Intensity score from 4.1 ± 0.4 before surgery to 2.1 ± 1.2 after surgery. Pain improvement after the surgery was documented in 95.9% of patients. Thirteen patients (17.6%) developed burning pain following surgery. Five patients developed complications (6.7%), including incisional infection, facial palsy, CSF leak, and hearing deficit, all of which were minor.CONCLUSIONS: Intraoperative injection of glycerin into the trigeminal nerve is a generally safe and potentially effective treatment for TN when no distinct site of arterial compression is identified during surgery or when decompression of the nerve is deemed to be inadequate.

17 June 2026
Verified
Other
Open access
APAyush Pant
Ayush Pant
AJAanchal Jain
Aanchal Jain
YCYiyun Chen
Yiyun Chen
KPKisha Patel
Kisha Patel
LSLaura Saleh
Laura Saleh
CJChristopher M. Jackson
Christopher M. Jackson
Figure S6: Ccr6 ablation delays tumor growth across multiple tumor models and CCR6CCL20 expression correlates with overall survival in cancer patients.